nach oben

Erschienen in:

01.05.2012 | Case Report

Development of interstitial pneumonia in a patient with rheumatoid arthritis induced by isoniazid for tuberculosis chemoprophylaxis

verfasst von: Kiyoshi Migita, Tetsuya Umeno, Kana Miyagawa, Yasumori Izumi, Eisuke Sasaki, Tomoyuki Kakugawa, Masahiro Ito, Akitoshi Kinoshita, Taichiro Miyashita

Erschienen in: Rheumatology International | Ausgabe 5/2012

Einloggen, um Zugang zu erhalten

Abstract

Here, we report a 56-year-old patient with rheumatoid arthritis (RA) who had been treated with methotrexate and sulfuasalazine, but the disease activity remained high. Therefore, we planned TNF-blocker treatment for this patient. A tuberculin skin test was positive, we started anti-tuberculosis (TB) chemoprophylaxis with isoniazid (INH). However, liver dysfunction was appeared after 2 weeks from the start of INH. Therefore, we discontinued INH transiently and tried the desensitization of INH. However, interstitial pneumonia was developed 2 weeks after the re-start of INH, we decided to stop the INH prophylaxis. Interstitial pneumonia was improved by corticosteroid treatments. This case report shows that INH-induced IP can be occurred during the course of anti-TB chemoprophylaxis in patients with RA.

Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V, Montero D, Pascual-Gómez E, Mola EM, Carreño L, Figueroa M, Group BIOBADASER (2005) Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 52:1766–1772PubMedCrossRef

Mor A, Bingham CO 3rd, Kishimoto M, Izmirly PM, Greenberg JD, Reddy S, Rosenthal PB (2008) Methotrexate combined with isoniazid treatment for latent tuberculosis is well tolerated in patients with rheumatoid arthritis: experience from an urban arthritis clinic. Ann Rheum Dis 67:462–465PubMedCrossRef

Miyai M, Tsubota T, Asano K (1989) Isoniazid-induced interstitial pneumonia. Respir Med 83:517–519PubMedCrossRef

Salomaa ER, Ruokonen EL, Tevola K, Tala E (1990) Pulmonary infiltrates and fever induced by isoniazid. Postgrad Med J 66:647–649PubMedCrossRef

Gómez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD, BIOBADASER Group (2003) Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 48:2122–2127PubMedCrossRef

Wolfe F, Michaud K, Anderson J, Urbansky K (2004) Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 50:372–379PubMedCrossRef

Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H, Kamatani N, Harigai M, Ryu J, Inoue K, Kondo H, Inokuma S, Ochi T, Koike T (2008) Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 67:189–194PubMedCrossRef

Miyasaka N, Takeuchi T, Eguchi K (2005) Proposed [corrected] Japanese guidelines for the use of infliximab for rheumatoid arthritis. Mod Rheumatol 15:4–8PubMedCrossRef

Anaya JM, Diethelm L, Ortiz LA, Gutierrez M, Citera G, Welsh RA, Espinoza LR (1995) Pulmonary involvement in rheumatoid arthritis. Semin Arthritis Rheum 24:242–254PubMedCrossRef

10.

Matsushima H, Sugita Y, Yanagisawa T, Ubukata M, Kurosawa T, Yoshida F, Kanazawa M (2003) A case of isoniazid sodium methanesulfonate induced interstitial pneumonia. Kekkaku 78:401–406PubMed

11.

Nishizawa Y, Yasui M, Yamamori C, Tagami A, Fujimura M, Nakao S (2004) A case of successful desensitization therapy for isoniazid-induced pneumonitis. Nihon Kokyuki Gakkai Zasshi 42:649–654PubMed

Titel: Development of interstitial pneumonia in a patient with rheumatoid arthritis induced by isoniazid for tuberculosis chemoprophylaxis
verfasst von: Kiyoshi Migita
Tetsuya Umeno
Kana Miyagawa
Yasumori Izumi
Eisuke Sasaki
Tomoyuki Kakugawa
Masahiro Ito
Akitoshi Kinoshita
Taichiro Miyashita
Publikationsdatum: 01.05.2012
Verlag: Springer-Verlag
Erschienen in: Rheumatology International / Ausgabe 5/2012
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-010-1441-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Development of interstitial pneumonia in a patient with rheumatoid arthritis induced by isoniazid for tuberculosis chemoprophylaxis

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2012

Prevalence of depression and depressive symptoms in patients with systemic lupus erythematosus: Iranian experience

Successful treatment with intravenous immunoglobulin of severe thrombocytopenia complicated in primary Sjögren’s syndrome

A case of brucellar monoarthritis and review of the literature

Power Doppler ultrasonography is useful for assessing disease activity and predicting joint destruction in rheumatoid arthritis patients receiving tocilizumab—preliminary data

Pneumorrhachis and pneumomediastinum in connective tissue disease-related interstitial lung disease: case series from a tertiary care teaching hospital in South India

Anti-PAD4 autoantibodies in rheumatoid arthritis: levels in serum over time and impact on PAD4 activity as measured with a small synthetic substrate

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin